Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02362503 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 87 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Completion moved earlier from Jan 28, 2027 to Oct 22, 2026 Site details revised at 2 of 139 sitesv87 Show 1 more changeShow less
    • Site details revised at 2 of 139 sites
  2. Completion date: Sep 30, 2026 to Jan 28, 2027 Site details revised at 1 of 139 sitesv86 Show 1 more changeShow less
    • Site details revised at 1 of 139 sites
  3. Completion date: Dec 31, 2025 to Sep 30, 2026v85
  4. Study sites: 138 to 139v84
  5. Completion date: Dec 31, 2026 to Dec 31, 2025 Site details revised at 90 of 138 sitesv83 Show 1 more changeShow less
    • Site details revised at 90 of 138 sites
Show 45 earlier versionsHide 45 earlier versions
  1. Completion date: Dec 31, 2025 to Dec 31, 2026v82
  2. Re-verified, no change to tracked fieldsv81
  3. Completion date: Dec 31, 2024 to Dec 31, 2025 Site details revised at 4 of 138 sitesv80 Show 1 more changeShow less
    • Site details revised at 4 of 138 sites
  4. 2 versions Re-verified since Aug 7, 2022, no change to tracked fieldsv78-v79
  5. Study sites: 139 to 138v77
  6. Study sites: 140 to 139v76
  7. Study sites: 139 to 140 Secondary endpoints revised (13)v75 Show 1 more changeShow less
    • Secondary endpoints revised (13)

    See this version in full on ClinicalTrials.gov ↗

  8. Publications: details revised at 1 of 10 entriesv74
  9. Study sites: 140 to 139v73
  10. Study sites: 162 to 140 Completion date: Apr 15, 2020 to Dec 31, 2024v72 Show 1 more changeShow less
    • Completion date: Apr 15, 2020 to Dec 31, 2024
  11. Re-verified, no change to tracked fieldsv71
  12. Results first posted: Sep 18, 2018 Enrollment target: 367 to 371 · Secondary endpoints revised (13) · Primary endpoint revised · 1 morev70 Show 4 more changesShow less
    • Enrollment target: 367 to 371
    • Secondary endpoints revised (13)
    • Primary endpoint revised
    • Site details revised at 1 of 162 sites

    See this version in full on ClinicalTrials.gov ↗

  13. Enrollment target: 371 to 367 Secondary endpoints: details revised at 10 of 13 entriesv69 Show 1 more changeShow less
    • Secondary endpoints: details revised at 10 of 13 entries
  14. Primary endpoint revised Secondary endpoints revised (13) · Site details revised at 1 of 162 sitesv68 Show 2 more changesShow less
    • Secondary endpoints revised (13)
    • Site details revised at 1 of 162 sites

    See this version in full on ClinicalTrials.gov ↗

  15. Re-verified, no change to tracked fieldsv67
  16. Primary endpoint revised Secondary endpoints: 7 to 13 · Site details revised at 1 of 162 sitesv66 Show 2 more changesShow less
    • Secondary endpoints: 7 to 13
    • Site details revised at 1 of 162 sites

    See this version in full on ClinicalTrials.gov ↗

  17. Start date: Mar 13, 2015 to Feb 23, 2015v65
  18. Re-verified, no change to tracked fieldsv64
  19. Enrollment target: estimated 370 to confirmed 371 Primary completion date changed from estimate of Apr 15, 2020 to Aug 18, 2016 · Site details revised at 9 of 162 sitesv63 Show 2 more changesShow less
    • Primary completion date changed from estimate of Apr 15, 2020 to Aug 18, 2016
    • Site details revised at 9 of 162 sites
  20. 2 versions Re-verified since Jan 12, 2018, no change to tracked fieldsv61-v62
  21. Enrollment target: 260 to 370 Site details revised at 2 of 162 sitesv60 Show 1 more changeShow less
    • Site details revised at 2 of 162 sites
  22. Site details revised at 1 of 162 sitesv59
  23. 2 versions Re-verified since Nov 6, 2017, no change to tracked fieldsv57-v58
  24. Site details revised at 1 of 162 sitesv56
  25. Re-verified, no change to tracked fieldsv55
  26. Study sites: 161 to 162v54
  27. Site details revised at 3 of 161 sitesv53
  28. Site details revised at 3 of 161 sitesv52
  29. Re-verified, no change to tracked fieldsv51
  30. Site details revised at 2 of 161 sitesv50
  31. Re-verified, no change to tracked fieldsv49
  32. Study sites: 156 to 161v48
  33. Study sites: 153 to 156v47
  34. Study sites: 154 to 153v46
  35. Primary completion date: Apr 1, 2020 to Apr 15, 2020 Start date: Mar 1, 2015 to Mar 13, 2015 · Site details revised at 1 of 154 sitesv45 Show 2 more changesShow less
    • Start date: Mar 1, 2015 to Mar 13, 2015
    • Site details revised at 1 of 154 sites
  36. Site details revised at 1 of 154 sitesv44
  37. Study sites: 155 to 154v43
  38. Site details revised at 4 of 155 sitesv42
  39. Lead sponsor: Bristol-Myers Squibb to ViiV Healthcare Enrollment target: 410 to 260 · Primary completion date: Sep 2016 to Apr 1, 2020 · Trial status: Recruiting to Active, Not Recruiting · 5 morev41 Show 8 more changesShow less
    • Enrollment target: 410 to 260
    • Primary completion date: Sep 2016 to Apr 1, 2020
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 166 to 155
    • Completion date: Aug 2018 to Apr 15, 2020
    • Start date: Feb 2015 to Mar 1, 2015
    • Eligibility criteria shortened, about 11 words
    • Secondary endpoints revised (7)

    See this version in full on ClinicalTrials.gov ↗

  40. Re-verified, no change to tracked fieldsv40
  41. Site details revised at 11 of 166 sitesv39
  42. Completion date: May 2018 to Aug 2018v38
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
Trial Details
NCT Number NCT02362503
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 371 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov